Could exercise hormone irisin be a therapeutic agent against Parkinson’s and other neurodegenerative diseases?
Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease (AD). The pathologic hallmarks of the disease are the loss of dopaminergic neurons of substantia nigra pars compacta and the presence of intraneuronal alpha synuclein (a-syn) aggregates. Clinical f...
Main Authors: | Konstantinos I. Avgerinos, Junli Liu, Maria Dalamaga |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-03-01
|
Series: | Metabolism Open |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2589936823000051 |
Similar Items
-
Alterations of the Adipo–Myokine Irisin in Sepsis and Septic Shock: Diagnostic and Prognostic Implications
by: Irene Karampela, et al.
Published: (2024-02-01) -
The Potential Role of Irisin in Vascular Function and Atherosclerosis: A Review
by: Kyeongho Byun, et al.
Published: (2020-09-01) -
Exercise-Induced Irisin Decreases Inflammation and Improves NAFLD by Competitive Binding with MD2
by: Weiwei Zhu, et al.
Published: (2021-11-01) -
Current Evidence of the Role of the Myokine Irisin in Cancer
by: Evangelia Tsiani, et al.
Published: (2021-05-01) -
Irisin, an Effective Treatment for Cardiovascular Diseases?
by: Chen Liu, et al.
Published: (2022-09-01)